Table 1.
Examples of oncolytic herpes simplex viruses (HSVs) currently under clinical trials.
| Virus | Transgene | Combination | Tumor Type | Phase | Reference |
|---|---|---|---|---|---|
| G207 | None | Radiation | Brain tumor | II | NCT04482933 |
| ONCR-177 | IL-12, CCL4, FLT3LG, αCTLA4 and αPD-1 | pembrolizumab | Melanoma and other solid tumors | I | NCT04348916 |
| OH2 (HSV-2) |
GM-CSF | Irinotecan or HX008 | Gastrointestinal tumors and other solid tumors | I & II | NCT03866525 |
| RP1 | GALV-GP and GM-CSF | None | Cutaneous squamous cell carcinoma | IB | NCT04349436 |
| RP1 | GALV-GP and GM-CSF | Cemiplimab | Cutaneous squamous cell carcinoma | I | NCT04050436 |
| RP2 | GALV-GP and GM-CSF | Nivolumab | Advanced solid tumors | i | NCT03767348 |
| T-VEC | GM-CSF | Ipilimumab and Nivolumab | Breast Cancer | I | NCT04185311 |
| T-VEC | GM-CSF | None | Angiosarcoma of skin | II | NCT03921073 |
| T-VEC | GM-CSF | Pembrolizumab | Sarcoma | II | NCT03069378 |
| T-VEC | GM-CSF | Pembrolizumab | Cutaneous melanoma | II | NCT03842943 |